SCHEDULE: SHN Financial Investments Exits Hepion Stake

S.H.N. Financial Investments Ltd. has amended its Schedule 13G, reporting zero beneficial ownership in Hepion Pharmaceuticals, Inc.

Summary

• S.H.N. Financial Investments Ltd. filed an Amendment No. 1 to its Schedule 13G regarding its holdings in Hepion Pharmaceuticals, Inc.
• The filing indicates that S.H.N. Financial Investments Ltd. now beneficially owns 0 shares of Hepion Pharmaceuticals, Inc. common stock, representing 0% of the class.
• This amends a previous Schedule 13G filed on January 27, 2025, which reported beneficial ownership of 1,060,883 shares purchased on January 22, 2025.
• Nir Shamir, Chief Executive Officer of S.H.N. Financial Investments Ltd., disclaims beneficial ownership of these securities for all other purposes, though he may be deemed to beneficially own them.

Sentiment

Score: 3

Explanation: The complete divestment by S.H.N. Financial Investments Ltd. from Hepion Pharmaceuticals, Inc. indicates a loss of confidence from this institutional investor, which can be perceived negatively by the market.

Negatives

• S.H.N. Financial Investments Ltd. has completely divested its 1,060,883 shares in Hepion Pharmaceuticals, Inc., reducing its beneficial ownership from a previously reported stake to 0%.

Future Outlook

No forward-looking statements or guidance are provided regarding Hepion Pharmaceuticals, Inc.'s future performance or strategic direction.

Management Comments

• Nir Shamir is the Chief Executive Officer of SHN. As such, SHN and Mr. Shamir may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the securities described herein. To the extent Mr. Shamir is deemed to beneficially own such securities, Mr. Shamir disclaims beneficial ownership of these securities for all other purposes.

Industry Context

This filing represents a standard disclosure of a change in institutional ownership, specifically a complete divestment. It does not provide broader industry trends or context beyond the specific transaction.

Stakeholder Impact

• Shareholders may view the complete divestment by an institutional investor as a negative signal, potentially impacting investor confidence and stock price.

Key Dates

Recommendation

The complete divestment by S.H.N. Financial Investments Ltd. from Hepion Pharmaceuticals, Inc. signals a lack of confidence from an institutional investor. While not a direct reflection of Hepion's fundamentals, such an exit can be interpreted by the market as a negative indicator, potentially leading to downward pressure on the stock price. Investors may consider selling or re-evaluating their positions given this institutional exit.

Keywords

Hepion Pharmaceuticals, SHN Financial Investments, Schedule 13G, Institutional Ownership, Equity Stake, Investment Exit, Common Stock